Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
04/12/2021 04/13/2021 04/14/2021 04/15/2021 04/16/2021 Date
102.7 102.1 107 104.8 105 Last
11943080 9906808 11579450 10385210 9211885 Volume
+0.69% -0.58% +4.80% -2.06% +0.19% Change
Financials
Sales 2020 5 491 M 842 M 842 M
Net income 2020 1 548 M 237 M 237 M
Net cash position 2020 4 659 M 715 M 715 M
P/E ratio 2020 209x
Yield 2020 -
Sales 2021 8 731 M 1 339 M 1 339 M
Net income 2021 2 410 M 370 M 370 M
Net cash position 2021 2 687 M 412 M 412 M
P/E ratio 2021 152x
Yield 2021 -
Capitalization 371 B 56 894 M 56 885 M
EV / Sales 2020 66,7x
EV / Sales 2021 42,2x
Nbr of Employees 6 646
Free-Float 79,6%
More Financials
Company
WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company‚Äôs primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs.... 
Sector
Pharmaceuticals
Calendar
08/23Earnings Release
More about the company
Notations Surperformance© of WuXi Biologics (Cayman) Inc.
Trading Rating : Investor Rating :
More Ratings
All news about WUXI BIOLOGICS (CAYMAN) INC.
04/02WUXI BIOLOGICS CAYMAN† : Shanghai Hile to Restructure Vaccine JV
MT
04/01WUXI BIOLOGICS CAYMAN† : Voluntary announcement restructuring of the wuxi vaccin..
PU
03/30WUXI BIOLOGICS CAYMAN† : Voluntary announcement establishment of joint venture
PU
03/29WUXI BIOLOGICS CAYMAN† : Nomura Adjusts WuXi Biologics' Price Target to HK$116.8..
MT
03/24WUXI BIOLOGICS CAYMAN† : (1) grant of restricted shares under restricted share a..
PU
03/24WUXI BIOLOGICS CAYMAN† : ' Profit Surges 43% in 2020 as Revenue Climbs 41%
MT
03/23WUXI BIOLOGICS CAYMAN† : List of directors and their roles and functions
PU
03/23WUXI BIOLOGICS CAYMAN† : Establishment of the environmental, social and governan..
PU
03/17WUXI BIOLOGICS CAYMAN† : Pfizer to halt biosimilar output in China, sell assets ..
RE
03/17Wuxi Biologics Shares Pull Back After Tuesday's Surge
DJ
03/17WUXI BIOLOGICS CAYMAN† : to Buy Pfizer's Biologics Manufacturing Site in China
MT
03/16WUXI BIOLOGICS CAYMAN† : Pfizer to halt biosimilar output in China, sell assets ..
RE
03/10WUXI BIOLOGICS CAYMAN† : CANbridge Pharmaceuticals Inc. - First Subject Dosed in..
AQ
02/26WUXI BIOLOGICS CAYMAN† : Date of board meeting
PU
02/03WUXI BIOLOGICS CAYMAN† : Expects Nearly $2 Billion from Private Placement
MT
More news
News in other languages on WUXI BIOLOGICS (CAYMAN) INC.
03/22STOCK MARKET PARIS : L'Amérique accélère, l'Europe s'enlise
03/22EN DIRECT DES MARCHES† : Veolia / Suez, Faurecia, Valneva, Quadient, Credit Suis..
03/17Le funambule Powell remonte en première ligne
03/17EN DIRECT DES MARCHES† : Stellantis, Faurecia, Orpea, Korian, BMW, Samsung, Baid..
03/10MÄRKTE ASIEN/Uneinheitlich - Verluste in Seoul und Sydney
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 103,34 CNY
Last Close Price 88,10 CNY
Spread / Highest target 54,8%
Spread / Average Target 17,3%
Spread / Lowest Target -23,3%
EPS Revisions
Managers and Directors
NameTitle
Zhi Sheng Chen Chief Executive Officer & Executive Director
Shao Hua Lu-Wong Chief Financial Officer
Ge Li Non-Executive Chairman
Weichang Zhou Executive Director, Chief Technology Officer & EVP
William Robert Keller Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
WUXI BIOLOGICS (CAYMAN) INC.2.14%56 894
CSL LIMITED-4.98%94 687
SAMSUNG BIOLOGICS CO.,LTD.0.61%49 298
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.18.65%43 060
BIOGEN INC.10.45%40 696
ALEXION PHARMACEUTICALS, INC.4.76%35 962